Phase 2
SNF472 significantly reduced progression of cardiovascular calcification in patients with end stage kidney disease (ESKD) receiving hemodialysis
Jonathan Cotliar, chief medical officer of Science 37, a leader in virtual clinical trials, took time to speak with BioSpace about virtual and hybrid clinical trials, the CNS Summit and Science 37.
In its announcement, Solid Biosciences said a patient in its second cohort who was dosed in October experienced a serious adverse event that was deemed related to the drug.
The drug failed to meet the primary endpoints of progression-free survival and overall response rate.
It was a busy week for clinical trial updates for the first week of November. Here’s a look.
Martinsried/ Munich Medigene AG announces that immune monitoring data during the first year of treatment from the ongoing Phase I / II clinical trial with Medigene’s DC vaccine for the treatment of acute myeloid leukemia will be presented at the upcoming ASH Annual Meeting taking place 7 - 10 December 2019 in Orlando, Florida, USA.
uniQure N.V. announced the publication of 26-week interim data from the ongoing Phase IIb clinical trial of etranacogene dezaparvovec, an investigational gene therapy for hemophilia B, in the journal, Blood Advances.
ORYX, a translational medicine company focused on oncolytic virotherapy and cancer vaccines, today published positive clinical trial results from a dose-escalating Phase I/IIa trial with oncolytic virus ParvOryx in metastatic, inoperable pancreatic cancer.
Studies Aim to Confirm Safety and Efficacy of Novel Bio-inspired Clot-dissolving Therapy
Cyclerion Therapeutics had a tough day, announcing the failure of two separate clinical trials for the same drug on the same day.
PRESS RELEASES